Premium
University of Chicago phase II consortium trial of selumetinib ( MEK i) demonstrates low tolerability and efficacy in relapsed DLBCL
Author(s) -
Galanitalie,
Smith Sonali M.,
Liao Chuanhong,
Petrich Adam,
Libao Bernadette,
Gartenhaus Ronald,
Westin Jason R.,
Cohen Kenneth S.,
Knost James A.,
Stadler Walter M.,
Doyle Austin,
Karrison Theodore,
Gordon Leo I.,
Evens Andrew M.
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14544
Subject(s) - selumetinib , medicine , cancer research , mek inhibitor , mapk/erk pathway , oncology , pharmacology , kinase , biology , microbiology and biotechnology